Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SLC 3010

Next Previous
Search
Drug Profile

SLC 3010

Alternative Names: SLC-3010

Latest Information Update: 23 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selecxine
  • Class Antibodies; Antineoplastics; Cytokines; Immunotherapies
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 19 Jan 2023 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Combination therapy, Second-line therapy or greater, Metastatic disease) in South Korea (IV) (NCT05525247)
  • 19 Jan 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Monotherapy, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in South Korea (IV) (NCT05525247)
  • 01 Sep 2022 Selecxine plans a phase I/II trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Inoperable/Unresectable) in USA (IV,Infusion) in October 2022 (NCT05525247)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top